Financial statements Farmaceutyczna Pracy Filofarm
Balance sheet data of FARMACEUTYCZNA PRACY FILOFARM
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
|---|---|---|---|---|---|---|
| Total assets | 37 333 047,64 | 39 268 113,93 | 39 500 236,83 | 39 715 821,49 | 40 427 735,24 | 39 305 444,97 |
| A. Fixed assets | 14 315 213,51 | 14 569 330,10 | 15 642 452,44 | 14 875 496,99 | 14 970 284,74 | 13 988 622,59 |
| B. Current assets | 22 997 775,70 | 24 309 405,62 | 23 693 750,08 | 24 762 495,75 | 25 356 345,46 | 25 127 681,71 |
| C. Share capital contributions (basic funds) | 20 058,43 | 389 378,21 | 164 034,31 | 77 828,75 | 101 105,04 | 189 140,67 |
| D. Own shares (stocks) | 0,00 | 0,00 | - | - | - | 0,00 |
| Total liabilities | 37 333 047,64 | 39 268 113,93 | 39 500 236,83 | 39 715 821,49 | 40 427 735,24 | 39 305 444,97 |
| A. Equity | 31 483 966,46 | 33 028 603,23 | 32 407 050,94 | 33 822 109,98 | 33 688 210,59 | 31 930 144,46 |
| B. Liabilities and provisions for liabilities | 5 849 081,18 | 6 239 510,70 | 7 093 185,89 | 5 893 711,51 | 6 739 524,65 | 7 375 300,51 |
| I. Long-term liabilities | 0,00 | 0,00 | 792 022,94 | 145 675,66 | 0,00 | 0,00 |
| II. Short-term liabilities | 3 868 776,72 | 3 925 867,39 | 3 693 932,60 | 3 484 641,91 | 4 594 897,63 | 4 633 054,76 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.